8-KEarningsReleaseQtr42013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2014
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
0-26224
51-0317849
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
311 Enterprise Drive
Plainsboro, NJ
(Address of principal executive offices)
08536
(Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 25, 2014, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2013 (the “Press Release”). A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item. In the financial statements portion of the Press Release, the Company has included a reconciliation of GAAP revenues to adjusted revenues for the quarter and year ended December 31, 2013, and GAAP net (loss)/income to adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) and adjusted EBITDA excluding stock-based compensation, GAAP net (loss)/income to adjusted net income, and GAAP (losses)/earnings per diluted share to adjusted earnings per diluted share used by management for the quarters and years ended December 31, 2013 and 2012, as well as GAAP net income to adjusted net income and GAAP earnings per diluted share to adjusted earnings per diluted share used by management for guidance for the year ending December 31, 2014. In addition, the Company included a supplemental disclosure of revenue by reporting segments in the financial statements portion of the Press Release.
The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide adjusted revenues, adjusted EBITDA, adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share. Adjusted revenues consist of growth in total revenues excluding the effects of currency exchange rates on the current period's revenues and the contribution of revenues from discontinued products in both the current and prior periods' revenues. The various measures of adjusted EBITDA consist of GAAP net (loss)/income, excluding: (i) depreciation and amortization, (ii) other income (expense), (iii) interest income and expense, (iv) income taxes, (v) those operating expenses also excluded from adjusted net income and, as appropriate (vi) stock-based compensation expense. The measure of adjusted net income consists of GAAP net (loss)/income, excluding: (i) manufacturing facility remediation costs; (ii) global enterprise resource planning (“ERP”) implementation charges; (iii) structural optimization charges; (iv) certain employee termination charges; (v) discontinued product lines charges; (vi) acquisition-related charges; (vii) certain expenses associated with product recalls; (viii) impairment charges; (ix) intangible asset amortization expense; (x) convertible debt non-cash interest; and (xi) income tax impact from adjustments and other items. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. Because the Company reported a GAAP net loss in the full year ended December 31, 2013, the calculation of GAAP diluted weighted average shares outstanding for the full year 2013 period excludes the effects of stock options and unvested restricted stock, as the effect of these equity awards would be anti-dilutive.

The Company believes that the presentation of adjusted revenues and the various adjusted EBITDA, adjusted net income and adjusted earnings per diluted share measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Management uses non-GAAP financial measures in the form of adjusted revenues, adjusted EBITDA, adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share when evaluating operating performance because we believe that the inclusion or exclusion of the items described below, for which the amounts and/or timing may vary significantly depending upon the Company's acquisition, integration, and restructuring activities, for which the amounts are non-cash in nature, or for which the amounts are not expected to recur at the same magnitude as we implement certain tax planning strategies, provides a supplemental measure of our operating results that facilitates comparability of our operating performance from period to period, against our business model objectives, and against other companies in our industry. We have chosen to provide this information to investors so they can analyze our operating results in the same way that management does and use this information in their assessment of our core business and the valuation of our Company.
Adjusted revenues, adjusted EBITDA, adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share are significant measures used by management for purposes of:
supplementing the financial results and forecasts reported to the Company's board of directors;
evaluating, managing and benchmarking the operating performance of the Company;
establishing internal operating budgets;
determining compensation under bonus or other incentive programs;
enhancing comparability from period to period;
comparing performance with internal forecasts and targeted business models; and
evaluating and valuing potential acquisition candidates.

The measure of adjusted revenues that we report reflects the reduction in total revenues for the quarter and year ended December 31, 2013 adjusted for the effects of currency exchange rates on current period revenues. We provide this measure because changes



in foreign currency exchange rates can distort our revenue reduction favorably or unfavorably, depending upon the strength of the U.S. dollar in relation to the various foreign currencies in which we generate revenues. We generate significant revenues outside the United States in multiple foreign currencies including euros, British pounds, Swiss francs and Australian and Canadian dollars. We believe this measure provides useful information to determine the success of our international selling organizations in increasing sales of products in their local currencies without regard to fluctuations in currency exchanges rates, which we have no control over.

The measure of adjusted net income reflects GAAP net income adjusted for one or more of the following items, as applicable:
Manufacturing facility remediation costs. These costs represent expenses associated with remediation and related unplanned idle time and underutilization at the Plainsboro, NJ and Añasco, Puerto Rico manufacturing facilities. Management excludes this item when evaluating the Company's operating performance because of the infrequent nature and the magnitude of this item.
Global ERP implementation charges. Systems implementation charges consist of the non-capitalizable portion of internal labor and outside consulting costs related to the implementation of a global ERP system. We have inherited many diverse business processes and different information systems through our numerous acquisitions. Accordingly, we are undertaking this initiative in order to standardize business processes globally and to better integrate all of our existing and acquired operations using one information system. Although recurring in nature given the expected timeframe to complete the implementation for our existing operations and our expectation to continue to acquire new businesses and operations, management excludes these charges when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's implementation activities. In addition, with the global ERP project continuing the application development phase and entering the testing phase, more costs of the project will be capitalized and, therefore, are not comparable to earlier periods.
Structural optimization charges. These charges, which include employee termination and other costs associated with exit or disposal of facilities, costs related to acquisition integration, costs related to transferring manufacturing and/or distribution activities to different locations, and rationalization or enhancement of our organization, result from rationalizing and enhancing our existing manufacturing, distribution, administrative, functional and commercial infrastructure. Some of these cost-saving and efficiency-driven activities are identified as opportunities in connection with acquisitions that provide the Company with additional capacity or economies of scale. Although recurring in nature given management's ongoing review of the efficiency of our organization and structure, including manufacturing, distribution and administrative facilities and operations, management excludes these items when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's rationalization activities and are, in some cases, dependent upon opportunities identified in acquisitions, which also vary in frequency and magnitude.
Certain employee termination charges. Certain employee termination and related charges consist of charges related to senior management level terminations and certain significant reductions in force that are not initiated in connection with restructuring. Management excludes these items when evaluating the Company's operating performance because these amounts do not affect our core operations and because of the infrequent and/or large scale nature of these activities.
Discontinued product lines charges. These charges represent charges taken in connection with product lines that the Company discontinues. Management excludes this item when evaluating the Company's operating performance because discontinued products do not provide useful information regarding the Company's prospects for future performance.
Acquisition-related charges. Acquisition-related charges include up-front fees and milestone payments that are expensed as incurred in connection with acquiring licenses or rights to technology for which no product has been approved for sale by regulatory authorities and such approval is not reasonably assured at the time such up-front fees or milestone payments are made, inventory fair value purchase accounting adjustments, changes in the fair value of contingent consideration after the acquisition date, and legal, accounting and other outside consultants expenses directly related to acquisitions or divestitures. Inventory fair value purchase accounting adjustments consist of the increase to cost of goods sold that occur as a result of expensing the “step up” in the fair value of inventory that we purchased in connection with acquisitions as that inventory is sold during the financial period. Although recurring given the ongoing character of our development and acquisition programs, these acquisition, divestiture and in-licensing related charges are not factored into the evaluation of our performance by management after completion of development programs or acquisitions because they are of a temporary nature, they are not related to our core operating performance and the frequency and amount of such charges vary significantly based on the timing and magnitude of our development, acquisition and divestiture transactions as well as the level of inventory on hand at the time of acquisition.




Certain expenses associated with product recalls. These costs represent expenses associated with a voluntary recall of certain products manufactured in the Añasco, Puerto Rico facility between December 2010 and May 2011 and between November 2012 and March 2013. Management excludes these items when evaluating the Company’s operating performance because of the infrequent and/or large scale nature of these activities.
Impairment charges. This primarily represents an impairment charge recorded against goodwill related to the Company’s U.S. Spine reporting unit during 2013. Goodwill impairment exists when the reporting unit’s goodwill exceeds its implied value. The decrease in the reporting unit’s implied fair value resulted primarily from declining financial performance caused by broader market issues as well as company specific issues.  The impairment charges category also includes non-goodwill related impairment charges recorded against various intangible assets such as completed or core technology, customer relationships, tradenames, and in-process research and development previously capitalized in connection with business combinations. Such impairments result primarily from management decisions to discontinue or significantly reduce promoting certain product lines or tradenames, the inability to incorporate existing product technologies into product development programs, and other circumstances.  Management excludes this item when evaluating the Company's operating performance because of the infrequent and non-cash nature of this activity.
Intangible asset amortization expense. Management excludes this item when evaluating the Company's operating performance because it is a non-cash expense.
Convertible debt non-cash interest. The convertible debt accounting requires separate accounting for the liability and equity components of the Company's convertible debt instruments, which may be settled in cash upon conversion, in a manner that reflects an applicable nonconvertible debt borrowing rate at the time that we issued such convertible debt instruments. Management excludes this item when evaluating the Company's operating performance because of the non-cash nature of the expense.
Income tax impact from adjustments and other items. Estimated impact on income tax expense related to the following:

(i)
Adjustments to income tax expense for the amount of additional tax expense that the Company estimates that it would record if it used non-GAAP results instead of GAAP results in the calculation of its tax provision, based on the statutory rate applicable to jurisdictions in which the above non-GAAP adjustments relate.
(ii)
Adjustments to income tax expense in the current quarter for the cumulative impact in that quarter of changes in income tax rates (statutory and estimated effective tax rates) and certain other infrequently occurring items that relate to prior periods. Management excludes these items when evaluating the Company's current quarter operating performance because the cumulative impact in the current quarter of these items applies to prior periods and thus distorts the Company's adjusted income tax rate in the current quarter. The year-to-date adjusted net income and adjusted diluted earnings per share measures are not adjusted by these items, as the cumulative impact is properly reflected in the year-to-date adjusted results.
Adjusted revenues, adjusted EBITDA, adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the revenues, costs or benefits associated with the operations of the Company's business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of the Company's results as reported under GAAP. The Company expects to continue to acquire businesses and product lines and to incur expenses of a nature similar to many of the non-GAAP adjustments described above, and exclusion of these items from its adjusted financial measures should not be construed as an inference that all of these revenue adjustments or costs are unusual, infrequent or non-recurring. Some of the limitations in relying on the adjusted financial measures are:
The Company periodically acquires other companies or businesses, and we expect to continue to incur acquisition-related expenses and charges in the future. These costs can directly impact the amount of the Company's available funds or could include costs for aborted deals which may be significant and reduce GAAP net income.
The Company has initiated a long-term effort to implement a global ERP system, and we expect to continue to incur significant systems implementation charges until that effort is completed. These costs can directly impact the amount of the Company's available funds and reduce GAAP net income.
All of the adjustments to GAAP net income have been tax affected at the Company's actual tax rates. Depending on the nature of the adjustments and the tax treatment of the underlying items, the effective tax rate related to adjusted net income could differ significantly from the effective tax rate related to GAAP net income.
 
In the financial tables portion of the Press Release, the Company has included a reconciliation of GAAP reported revenues to adjusted revenues for the quarter and year ended December 31, 2013 and GAAP net (loss)/ income to adjusted EBITDA and adjusted EBITDA excluding stock-based compensation, GAAP net (loss)/income to adjusted net income, and GAAP (losses)/earnings per diluted share to adjusted earnings per diluted share used by management for the quarters and years ended December 31, 2013 and 2012. Also included are reconciliations for future periods.




ITEM 7.01 REGULATION FD DISCLOSURE     
Attached as Exhibit 99.1, and incorporated into this Item 7.01 by reference, is the Press Release issued on February 25, 2014 by the Company.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release with attachments, dated February 25, 2014, issued by Integra LifeSciences Holdings Corporation




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
 
 
 
 
 
 
 
By:
 /s/ John B. Henneman, III
 
 
John B. Henneman, III
 
Title:
Corporate Vice President, Finance and Administration, and Chief Financial Officer
 
 
 
Date: February 25, 2014
 
 
 
 
 
 
 
 




EXHIBIT INDEX


 
 
 
Exhibit No.
Description
99.1
Press Release with attachments, dated February 25, 2014, issued by Integra LifeSciences Holdings Corporation



 

Ex 99.1 - Q4 2013 Earnings


EXHIBIT 99.1
News Release    
Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III                    Investor Relations:
Corporate Vice President,                 Angela Steinway
Finance and Administration,                 (609) 936-2268
and Chief Financial Officer                            
(609) 275-0500     angela.steinway@integralife.com
    
Integra LifeSciences Reports Fourth Quarter 2013 Financial Results
Increases Fourth Quarter Revenues 3% to $221 Million
Introduces 2014 Full-Year Guidance

Plainsboro, New Jersey, February 25, 2014 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported its financial results for the fourth quarter ending December 31, 2013. Total revenues for the fourth quarter were $220.8 million, reflecting an increase of $6.3 million, or 3.0%, over the fourth quarter of 2012. Total revenues in the full year of 2013 were $836.2 million, reflecting an increase of $5.3 million, or 0.6%, over 2012.
Excluding the contribution of revenues from discontinued products, revenues increased 3.5% over the fourth quarter of 2012 and 1.2% over the full year 2012. Currency had a negligible impact on revenues in both the quarter and full year periods.
The Company reported GAAP net income of $12.2 million, or $0.40 per diluted share, for the fourth quarter of 2013, compared to GAAP net income of $12.8 million, or $0.46 per diluted share, for the fourth quarter of 2012. The Company reported GAAP net loss of $(17.0) million, or $(0.60) per diluted share, for the full year 2013, compared to GAAP net income of $41.2 million, or $1.44 per diluted share in 2012.
Net income for the fourth quarter of 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $23.8 million, or $0.78 per diluted share, compared to adjusted net income of $22.0 million, or $0.78 per diluted share, in the fourth quarter of 2012. Adjusted net income for the full year 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $70.6 million, or $2.45 per diluted share, compared to $87.2 million, or $3.06 per diluted share in 2012.
“Our organization overcame significant challenges in 2013, and I am excited about the opportunities ahead,” said Peter Arduini, President and Chief Executive Officer. “Our quality and operations teams are strengthened and stabilized, and our commercial teams are launching significant new products, including DuraSeal(R) product lines and our Titan(TM) Shoulder System. We look forward to making further headway on our strategic optimization and growth objectives in 2014.”
Integra generated $11.7 million of cash flows from operations and invested $10.1 million in capital expenditures in the fourth quarter of 2013. For the full year ended December 31, 2013, Integra's cash flows from operations totaled $53.3 million and cash invested in capital expenditures was $47.9 million.
Adjusted EBITDA for the fourth quarter of 2013 was $43.1 million, an increase from $40.7 million in the fourth quarter of the prior year. Adjusted EBITDA excluding stock-based compensation for the fourth quarter of 2013 was $45.9 million, an increase from $43.1 million in the fourth quarter of the prior year. Adjusted EBITDA for the full year 2013 was $138.9 million, a decrease of 16.5% compared to the prior year. Adjusted EBITDA excluding stock-based compensation for the full year 2013 was $149.3 million, a decrease of 14.9% compared to the prior year.





Outlook for 2014
The Company expects 2014 revenues for the full year to be between $920 million and $940 million. The Company expects its GAAP earnings per diluted share for the full year to be between $1.46 and $1.64 and adjusted earnings per diluted share to be between $3.00 and $3.18. This guidance includes the contribution expected from the DuraSeal acquisition, which was completed on January 15, 2014.
“Our plan for 2014 anticipates strong execution, both by our sales organizations and on the cost savings initiatives underway," said Jack Henneman, Chief Financial Officer. “We expect to improve both profit margins and cash flow substantially versus 2013."
Integra plans to report DuraSeal revenues in its U.S. Neurosurgery and International business segments. Further, the Company expects to provide total revenue contribution from this acquisition during 2014.
In accordance with our usual practice, expectations for financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed.
In the future, the Company may record, or expects to record, certain additional revenues, gains, expenses or charges as described in the Discussion of Adjusted Financial Measures below that it will exclude in the calculation of adjusted EBITDA and adjusted earnings per share for historical periods and in providing adjusted earnings per share guidance.

Conference Call
Integra has scheduled a conference call for 8:30 AM ET today, Tuesday, February 25, 2014 to discuss financial results for the fourth quarter and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question and answer session following the call.
Access to the live call is available by dialing 913-312-0420 and using the passcode 5662291. The call can also be accessed through a webcast via a link provided on the Investor Relations homepage of Integra's website at investor.integralife.com. Access to the replay is available through March 15, 2014 by dialing 719-457-0820 and using the passcode 5662291. The webcast will also be archived on the website.









***
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect the Company's judgment as of the date of this release. Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, GAAP and adjusted net (loss)/income, GAAP and adjusted (loss)/earnings per diluted share, non-GAAP adjustments such as global enterprise resource planning ("ERP") system implementation charges, certain expenses associated with product recalls, acquisition-related charges, goodwill impairment charges, non-cash amortization of imputed interest for convertible debt, intangible asset amortization, and income tax expense (benefit) related to non-GAAP adjustments. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to: the Company's ability to execute its operating plan effectively, the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demand; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic conditions; continued weakness in sales outside of the U.S.; the Company's ability to manage its direct sales channels effectively; the Company's ability to maintain relationships with customers of acquired entities; physicians' willingness to adopt and third-party payors' willingness to provide reimbursement for the Company's recently launched and planned products; initiatives launched by the Company's competitors; downward pricing pressures for customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospital spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with recently enacted regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the Company's ability to integrate acquired businesses; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the amount and timing of acquisition and integration related costs; the geographic distribution of where the Company generates its taxable income; the effect of legislation effecting healthcare reform in the United States and internationally; fluctuations in foreign currency exchange rates; the amount of our convertible notes and bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological and other risk factors and uncertainties identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide adjusted revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share. Adjusted revenues consist of growth in total revenues excluding the effects of currency exchange rates on the current period's revenues and the contribution of revenues from discontinued products in both the current and prior periods' revenues.  The various measures of adjusted EBITDA consist of GAAP net (loss)/income, excluding: (i) depreciation and amortization, (ii) other income (expense), net, (iii) interest income and expense, (iv) income taxes, (v) those operating expenses also excluded from adjusted net income and, as appropriate (vi) stock-based compensation expense. The measure of adjusted net income consists of GAAP net (loss)/income, excluding: (i) manufacturing facility remediation costs; (ii) global ERP implementation




charges; (iii) structural optimization charges; (iv) certain employee termination charges; (v) discontinued product lines charges; (vi) acquisition-related charges; (vii) certain expenses associated with product recalls; (viii) impairment charges; (ix) intangible asset amortization expense; (x) convertible debt non-cash interest; and (xi) income tax impact from adjustments and other items. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding.  Because the Company reported a GAAP net loss during the full year ended December 31, 2013, the calculation of GAAP diluted weighted average shares outstanding for the full year 2013 period excludes the effects of stock options and unvested restricted stock, as the effect of these equity awards would be anti-dilutive.

Reconciliations of GAAP revenues to adjusted revenues for the quarter and year ended December 31, 2013 and GAAP net (loss)/income to adjusted EBITDA, adjusted EBITDA excluding stock-based compensation and adjusted net income, and GAAP (losses)/earnings per diluted share to adjusted earnings per diluted share for the quarters and years ended December 31, 2013 and 2012 appear in the financial tables in this release.

Integra believes that the presentation of adjusted revenues and the various adjusted EBITDA, adjusted net income, and adjusted earnings per diluted share measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.






INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

(In thousands, except per share amounts)
 
Three Months Ended
December 31,
 
Twelve Months Ended
December 31,
 
2013
 
2012
 
2013
 
2012
Total revenues
$
220,769

 
$
214,432

 
$
836,214

 
$
830,871

 
 
 
 
 
 
 
 
Costs and expenses:
 
 
 
 
 
 
 
Cost of goods sold
86,648

 
81,930

 
334,085

 
314,427

Research and development
14,511

 
12,864

 
52,088

 
51,012

Selling, general and administrative
98,537

 
96,529

 
394,250

 
373,114

Intangible asset amortization
3,037

 
4,551

 
12,697

 
18,536

Goodwill impairment charge

 

 
46,738

 

Total costs and expenses
202,733

 
195,874

 
839,858

 
757,089

Operating income (loss)
18,036

 
18,558

 
(3,644
)
 
73,782

Interest income
53

 
312

 
443

 
1,205

Interest expense
(4,707
)
 
(1,656
)
 
(19,788
)
 
(22,237
)
Other income (expense), net
(257
)
 
(603
)
 
(1,801
)
 
(721
)
Income (loss) before income taxes
13,125

 
16,611

 
(24,790
)
 
52,029

Income tax expense (benefit)
942

 
3,825

 
(7,813
)
 
10,825

Net income (loss)
12,183

 
12,786

 
(16,977
)
 
41,204

Diluted net income (loss) per share
$
0.40

 
$
0.46

 
$
(0.60
)
 
$
1.44

Weighted average common shares outstanding for diluted net income (loss) per share
30,636

 
28,064

 
28,416

 
28,516














Segment revenues and growth in total revenues excluding the effects of currency exchange rates are as follows:
(In thousands)
 
Three Months Ended
December 31,
 
Twelve Months Ended
December 31,
 
2013
2012
Change
 
2013
2012
Change
U.S. Neurosurgery
$46,373
$45,502
1.9%
 
$172,250
$171,278
0.6%
U.S. Instruments
40,890
41,591
(1.7)%
 
159,627
162,323
(1.7)%
U.S. Extremities
36,243
31,251
16.0%
 
134,683
122,847
9.6%
U.S. Spine & Other
46,526
47,725
(2.5)%
 
179,940
190,546
(5.6)%
International *
50,737
48,363
4.9%
 
189,714
183,877
3.2%
Total Revenue
$220,769
$214,432
3.0%
 
$836,214
$830,871
0.6%
 
 
 
 
 
 
 
 
Impact of changes in currency exchange rates
$
(5
)
$—
 
 
$
(238
)
$—
 
Total revenues excluding the effects of currency exchange rates
$220,764
$214,432
3.0%
 
$835,976
$830,871
0.6%
 
 
 
 
 
 
 
 
Total Revenue
$220,769
$214,432
3.0%
 
$836,214
$830,871
0.6%
Contribution of revenues from discontinued products**
$3,152
$4,200
(25.0)%
 
$13,432
$17,754
(24.3)%
Total revenues excluding the contribution of revenues from discontinued products
$217,617
$210,232
3.5%
 
$822,782
$813,117
1.2%

*The International segment revenues reflect sales that are actively managed by our International division. This does not constitute all recorded sales outside the U.S., as some Instrument sales and private label (included in U.S. Spine & Other) product sales in those regions are managed by their respective U.S. divisions.

** The Company has made some changes to the products included in the category of revenues identified for discontinuation. Certain Private Label revenues were previously included in this category because they had been substantially reduced or eliminated because Integra's customers found other sources during the supply disruptions earlier this year. At this time, a subset of these revenues are now expected to recover, albeit to a lower level. As a result, these have been eliminated from the revenue disclosure and revised for the historical periods accordingly. In addition, a small product line was identified for discontinuation in our International business and was added to this amount for historical periods included in this report.











Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended December 31, 2013
Item
Total Amount
COGS(a)
SG&A(b)
R&D (c)
Amort.(d)
Interest Exp(Inc)(e)
Tax(f)
Manufacturing facility remediation costs
$381
$381
$—
$—
$—
$—
$—
Certain expenses associated with product recalls
1,987
1,987
Global ERP implementation charges
5,549
5,549
Structural optimization charges
1,763
781
982
Certain employee termination charges
1,175
635
540
Acquisition-related charges
2,120
1,447
45
628
Impairment charges
340
340
Intangible asset amortization expense
4,721
1,684
3,037
Convertible debt non-cash interest
1,598
1,598
Estimated income tax impact from adjustments and other items
(8,031)
(8,031)
Depreciation expense*
7,007
 
 
 
 
 
 
Stock-based compensation expense
2,798
 
 
 
 
 
 

*For the period ending December 31, 2013, "Depreciation expense" excludes $(413) already included in "Structural optimization charges" above.

a)
COGS - Cost of goods sold
b)
SG&A - Selling, general and administrative
c)
R&D - Research and development
d)
Amort. - Intangible asset amortization
e)
Interest Inc (Exp) - Interest income (expense), net
f)
Tax - Income tax expense












Three Months Ended December 31, 2012
(In thousands)
Item
Total Amount
COGS (a)
SG&A (b)
Amort. (c)
Interest Exp/(Inc) (d)
Tax (e)
Manufacturing facility remediation costs
$746
$746
$—
$—
$—
$—
Global ERP implementation charges
4,287
4,287
Structural optimization charges
2,617
838
1,779
Certain employee termination charges
217
156
61
Discontinued product lines charges
310
310
Acquisition-related charges
485
485
Intangible asset amortization expense
6,132
1,582
4,550
Convertible debt non-cash interest
236
236
Estimated income tax impact from adjustments and other items
(5,850)
(5,850)
Depreciation expense
7,357
 
 
 
 
 
Stock-based compensation expense
2,420
 
 
 
 
 


a)
COGS - Cost of goods sold
b)
SG&A - Selling, general and administrative
c)
Amort. - Intangible asset amortization
d)
Interest Inc(Exp) - Interest income (expense), net
e)
Tax - Income tax expense






Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Twelve Months Ended December 31, 2013
Item
Total Amount
COGS(a)
SG&A(b)
R&D (c)
Amort.(d)
Goodwill (e)
Interest Exp(Inc)(f)
Tax(g)
Manufacturing facility remediation costs
$8,230
$7,948
$282
$—
$—
$—
$—
$—
Certain expenses associated with product recalls
3,431
3,266
165
Global ERP implementation charges
24,264
24,264
Structural optimization charges
8,793
4,105
4,688
Certain employee termination charges
1,205
665
540
Acquisition-related charges
3,113
2,169
316
628
Intangible asset amortization expense
19,390
6,693
12,697
Impairment charges
47,078
340
46,738
Convertible debt non-cash interest
6,463
6,463
Estimated income tax impact from adjustments and other items
(34,428)
(34,428)
Depreciation expense*
27,088
 
 
 
 
 
 
 
Stock-based compensation expense
10,393
 
 
 
 
 
 
 

*For the period ending December 31, 2013, "Depreciation expense" excludes $532 already included in "Structural optimization charges" above.

a)
COGS - Cost of goods sold
b)
SG&A - Selling, general and administrative
c)
R&D - Research and development
d)
Amort. - Intangible asset amortization
e)
Goodwill - Goodwill impairment charge
f)
Interest Inc (Exp) - Interest income (expense), net
g)
Tax - Income tax expense










Twelve Months Ended December 31, 2012
(In thousands)
Item
Total Amount
COGS (a)
SG&A (b)
Amort. (c)
Interest Exp(Inc) (d)
Tax (e)
Manufacturing facility remediation costs
$7,939
$7,939
$—
$—
$—
$—
Global ERP implementation charges
16,384
16,384
Structural optimization charges
10,098
3,720
6,378
Certain employee termination charges
1,356
449
907
Discontinued product lines charges
1,368
1,368
Acquisition-related charges
2,808
2,808
Impairment charges
141
141
Intangible asset amortization expense*
24,991
6,455
18,536
Convertible debt non-cash interest
8,520
8,520
Estimated income tax impact from adjustments and other items
(27,590)
(27,590)
Depreciation expense
27,479
 
 
 
 
 
Stock-based compensation expense
9,051
 
 
 
 
 

* This amount excludes $141 of intangible asset amortization expense included in "impairment charges" above.

a)
COGS - Cost of goods sold
b)
SG&A - Selling, general and administrative
c)
Amort. - Intangible asset amortization
d)
Interest Inc(Exp) - Interest income (expense), net
e)
Tax - Income tax expense








INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET (LOSS)/INCOME TO ADJUSTED EBITDA AND ADJUSTED EBITDA EXCLUDING STOCK BASED COMPENSATION
(UNAUDITED)

(In thousands)
 
Three Months Ended
December 31,
 
Twelve Months Ended
December 31,
 
2013
 
2012
 
2013
 
2012
 
 
 
 
 
 
 
 
GAAP net (loss)/income
$
12,183

 
$
12,786

 
$
(16,977
)
 
$
41,204

Non-GAAP adjustments:
 
 
 
 
 
 
 
Depreciation and intangible asset amortization expense
11,728

 
13,489

 
46,478

 
52,470

Other (income) expense, net
257

 
603

 
1,801

 
721

Interest (income) expense, net
4,654

 
1,344

 
19,345

 
21,032

Income tax expense (benefit)
942

 
3,825

 
(7,813
)
 
10,825

Manufacturing facility remediation costs
381

 
746

 
8,230

 
7,939

Certain expenses associated with product recalls
1,987

 

 
3,431

 

Global ERP implementation charges
5,549

 
4,287

 
24,264

 
16,384

Structural optimization charges
1,763

 
2,617

 
8,793

 
10,098

Certain employee termination charges
1,175

 
217

 
1,205

 
1,356

Discontinued product lines charges

 
310

 

 
1,368

Acquisition-related charges
2,120

 
485

 
3,113

 
2,808

Impairment charges
340

 

 
47,078

 
141

     Total of non-GAAP adjustments
30,896

 
27,923

 
155,925

 
125,142

Adjusted EBITDA
$
43,079

 
$
40,709

 
$
138,948

 
$
166,346

Stock-based compensation
2,798

 
2,420

 
10,393

 
9,051

Adjusted EBITDA excluding stock-based compensation
$
45,877

 
$
43,129

 
$
149,341

 
$
175,397

 





INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET (LOSS)/INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)


(In thousands, except per share amounts)
 
Three Months Ended
December 31,
 
Twelve Months Ended
December 31,
 
2013
 
2012
 
2013
 
2012
 
 
 
 
 
 
 
 
GAAP net (loss) / income
$
12,183

 
$
12,786

 
$
(16,977
)
 
$
41,204

Non-GAAP adjustments:
 
 
 
 
 
 
 
Manufacturing facility remediation costs
381

 
746

 
8,230

 
7,939

Certain expenses associated with product recalls
1,987

 

 
3,431

 

Global ERP implementation charges
5,549

 
4,287

 
24,264

 
16,384

Structural optimization charges
1,763

 
2,617

 
8,793

 
10,098

Certain employee termination charges
1,175

 
217

 
1,205

 
1,356

Discontinued product lines charges

 
310

 

 
1,368

Acquisition-related charges
2,120

 
485

 
3,113

 
2,808

Intangible asset amortization expense
4,721

 
6,132

 
19,390

 
24,991

Impairment charges
340

 

 
47,078

 
141

Convertible debt non-cash interest
1,598

 
236

 
6,463

 
8,520

Estimated income tax impact from adjustments and other items
(8,031
)
 
(5,850
)
 
(34,428
)
 
(27,590
)

 
 
 
 
 
 
 
     Total of non-GAAP adjustments
11,603

 
9,180

 
87,539

 
46,015

Adjusted net income
$
23,786

 
$
21,966

 
$
70,562

 
$
87,219

Adjusted diluted net income per share
$
0.78

 
$
0.78

 
$
2.45

 
$
3.06

Weighted average common shares outstanding for diluted net (loss)/income per share
30,636

 
28,064

 
28,416

 
28,516

Non-GAAP adjustment for dilutive effects of equity awards

 

 
386

 

Weighted average common shares outstanding for adjusted diluted net income per share
30,636

 
28,064

 
28,802

 
28,516










INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED BALANCE SHEET DATA
(UNAUDITED)


(In thousands)
 
 
December 31,
 
December 31,
 
 
2013
 
2012
 
 
 
 
 
Cash and cash equivalents
 
$
120,614

 
$
96,938

Accounts receivable, net
 
118,145

 
114,916

Inventory, net
 
213,431

 
171,806

 
 
 
 
 
Bank line of credit
 
186,875

 
321,875

Convertible securities
 
205,182

 
197,672

 
 
 
 
 
Stockholders' equity
 
670,180

 
517,775








INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE


(In thousands, except per share amounts)
 
Projected Year Ended
 
December 31, 2014
 
Low
High
GAAP net income
$
48,200

$
54,200

Non-GAAP adjustments:
 
 
Global ERP implementation charges
23,100

23,100

Structural optimization charges
20,700

20,700

Acquisition-related charges
7,600

7,600

Intangible asset amortization expense
22,500

22,500

Convertible debt non-cash interest
6,800

6,800

Estimated income tax impact from adjustments and other items
(30,000
)
(30,000
)
 
 
 
Total of non-GAAP adjustments
50,700

50,700

Adjusted net income
$
98,900

$
104,900

GAAP diluted net income per share
$
1.46

$
1.64

Non-GAAP adjustments detailed above (per share)
$
1.54

$
1.54

Adjusted diluted net income per share
$
3.00

$
3.18

Weighted average common shares outstanding for diluted net income per share
33,000

33,000








Items included in GAAP net income guidance and location where each item is expected to be recorded is as follows:
(In thousands)
Projected Year Ended December 31, 2014

Item
Total Amount
COGS
SG&A
Amort.
Interest Exp(Inc)
Tax
Global ERP implementation charges
23,100
23,100
Structural optimization charges
20,700
18,500
2,200
Acquisition-related charges
7,600
1,100
6,500
Intangible asset amortization expense
22,500
6,700
15,800
Convertible debt non-cash interest
6,800
6,800
Estimated income tax impact from adjustments and other items
(30,000)
(30,000)

Source: Integra LifeSciences Holdings Corporation